Primary objective

To assess whether (i) a combination antiviral therapy of two DAA (nirmatrelvir/r + remdesivir) and/or (ii) an increase in nirmatrelvir/r duration from 5 to 10 days improves viral efficacy by decreasing the SARS-CoV-2 positivity rate by real time RT-PCR (CT<32) in nasopharyngeal swabs at D10.